Davidf Mcdermott News Today

David F. McDermott, MD, discusses the ongoing, randomized, phase 1/2 LITESPARK-024 trial in patients with advanced renal cell carcinoma, highlighting the eligibility criteria for this clinical trial.

David F. McDermott, MD, discusses how combining HIF-2α inhibition with CDK4/6 inhibition could be an effective treatment regimen in patients with renal cell carcinoma and shared details from the LITESPARK-024 trial.

David F. McDermott, MD, discusses the randomized phase 2 LITESPARK-024 trial (NCT05468697).

Date Time Dana-Farber research leads to better understanding of immune system in kidney cancer Two research papers highlight single-cell dissection of kidney tumors to identify new immunotherapy treatments and targets In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn’t work for all patients, and almost all patients, no matter how th...